Nacuity Pharmaceuticals is an Australian clinical-stage biotechnology company developing Nrf2 activator compounds for the treatment of degenerative diseases. The company's lead compound, NPI-001, is a potent and selective Nrf2 activator being developed initially for retinitis pigmentosa (RP), with preclinical programs in Alzheimer's disease and other neurodegenerative conditions. Nacuity's proprietary chemical library of Nrf2 activators offers advantages in potency, selectivity, and blood-retinal/barrier penetration compared to earlier-generation compounds like dimethyl fumarate or bardoxolone methyl.
Company Information
| Attribute | Details | |-----------|---------| | Headquarters | Brisbane, Queensland, Australia | | Founded | 2012 (spun out from The University of Queensland) | | CEO | Dr. David Christoffel | | Website | https://www.nacuity.com | | Funding | Series B (2023), NIH grants, Save Sight Inc. partnership | | Stage | Phase 2 (retinitis pigmentosa), Preclinical (AD) |
Science and Technology
Nrf2 Activation Platform
Nacuity's technology is based on a platform of small molecule Nrf2 activators that work by disrupting the Keap1-Nrf2 interaction:
Target: The interface between [KEAP1](/genes/keap1) (Kelch-like ECH-associated protein 1) and [NFE2L2/Nrf2](/genes/nfe2l2)
Mechanism: Small molecules bind at the Keap1-Nrf2 binding interface, releasing Nrf2 from cytosolic sequestration
Result: Stabilized Nrf2 translocates to the nucleus and activates Antioxidant Response Element (ARE)-driven gene expression
Potency: Sub-nanomolar EC50 for Nrf2 activation in cellular assays
Selectivity: Minimal off-target kinase activity
Pharmacokinetics: Oral bioavailability >60%, brain and retinal exposure in preclinical species
Safety: Clean off-target profile, no genotoxicity, acceptable tolerability in GLP toxicology
Clinical Programs
NPI-001 in Retinitis Pigmentosa — Phase 2
Nacuity's most advanced program targets retinitis pigmentosa, a genetic degenerative eye disease sharing biological parallels with neurodegeneration in the brain:
Rationale: Oxidative stress is a key driver of photoreceptor death in RP. Nrf2 activation upregulates antioxidant defenses specifically in retinal pigment epithelium (RPE) and photoreceptor cells
Preclinical data: NPI-001 preserved photoreceptor function in multiple rodent models of RP (rd1, rd10 mice; rhodopsin P23H rats)[@npi001_rp]
Phase 2 trial: Multi-center, randomized, placebo-controlled study
Partnership: Funded in part by Save Sight Inc., with NIH/NEI support
NPI-001 in Alzheimer's Disease — Preclinical
While the primary RP program advances, Nacuity is building the AD case:
Scientific rationale: Oxidative stress, mitochondrial dysfunction, and neuroinflammation all drive AD progression. Nrf2 activation addresses all three through transcriptional upregulation of protective genes
Preclinical data: NPI-001 reduced amyloid-beta and tau pathology in 3xTg AD mice (data presented at conferences)
Status: IND-enabling studies ongoing; first-in-human AD study planned 2025-2026
Broader Pipeline
| Program | Indication | Stage | Status | |---------|------------|-------|--------| | NPI-001 RP | Retinitis pigmentosa | Phase 2 | Active 2024 | | NPI-001 AD | Alzheimer's disease | Preclinical | IND-enabling | | NPI-002 | Neurodegeneration | Discovery | Lead optimization | | NPI-003 | CNS oxidative stress | Discovery | Hit-to-lead |
Mechanism Context
Nrf2 in Neurodegeneration
The [Nrf2-ARE pathway](/mechanisms/nrf2-keap1-pathway) is a central therapeutic target in neurodegeneration:
Alzheimer's disease: Nrf2 activation counteracts amyloid-beta and tau-induced oxidative stress, supports mitochondrial function via PGC-1alpha, and suppresses neuroinflammation through NF-kappaB cross-talk[@oxidative_neuro]
Parkinson's disease: Nrf2 dysfunction documented in PD substantia nigra. Activation protects dopaminergic neurons from oxidative damage from dopamine quinones, mitochondrial Complex I deficiency, and microglial ROS production
Retinitis pigmentosa: Photoreceptors are highly vulnerable to oxidative stress due to high metabolic activity and light-induced ROS generation. Nrf2 activation in RPE cells provides cytoprotection
[NPI-001 Phase 2 Trial in Retinitis Pigmentosa — ClinicalTrials.gov](https://clinicaltrials.gov)
[Bahn et al., NRF2 activation as therapeutic strategy in neurodegeneration — Expert Opinion on Therapeutic Targets (2019)](https://doi.org/10.1080/14728222.2019.1660133)